EMD-27354

Single-particle
25.0 Å
EMD-27354 Deposition: 19/06/2022
Map released: 21/06/2023
Last modified: 19/07/2023
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-27354

nsEM map of hemagglutinin H1 A/Mich/045/15 complexed with polyclonal Fab samples from individual 182419 at day 70 using Sulfo-SDAD photo-cross-linker

EMD-27354

Single-particle
25.0 Å
EMD-27354 Deposition: 19/06/2022
Map released: 21/06/2023
Last modified: 19/07/2023
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: nsEM map of hemagglutinin H1 A/Mich/045/15 complexed with polyclonal Fab samples from individual 182419 at day 0

Deposition Authors: Torrents de la Pena A , Sewall LM , Ward AB
Increasing sensitivity of antibody-antigen interactions using photo-cross-linking.
PUBMED: 37426749
DOI: doi:10.1016/j.crmeth.2023.100509
ISSN: 2667-2375
Abstract:
Understanding antibody-antigen interactions in a polyclonal immune response in humans and animal models is critical for rational vaccine design. Current approaches typically characterize antibodies that are functionally relevant or highly abundant. Here, we use photo-cross-linking and single-particle electron microscopy to increase antibody detection and unveil epitopes of low-affinity and low-abundance antibodies, leading to a broader structural characterization of polyclonal immune responses. We employed this approach across three different viral glycoproteins and showed increased sensitivity of detection relative to currently used methods. Results were most noticeable in early and late time points of a polyclonal immune response. Additionally, the use of photo-cross-linking revealed intermediate antibody binding states and demonstrated a distinctive way to study antibody binding mechanisms. This technique can be used to structurally characterize the landscape of a polyclonal immune response of patients in vaccination or post-infection studies at early time points, allowing for rapid iterative design of vaccine immunogens.